✨ Medicines Distribution Consents




28 OCTOBER NEW ZEALAND GAZETTE 3201

Dated this 20th day of October 1993.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go9113

Consent to the Distribution of Changed Medicines

Pursuant to section 24(5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Clarithromycin 125 mg/5 ml, Granules for oral suspension Abbott Laboratories Limited, Queenborough, Kent, Great Britain, Abbott Australasia Pty Limited, Kurnell, New South Wales, Australia and Abbott S.p.A., Campoverde de Aprilia, Latina, Italy Klacid Paediatric Suspension
250 mg/5 ml
Clarithromycin 500 mg Powder for reconstitution for injection le laboratoire Abbott France, Usine de l’Isle, Saint-Remy-Sur-Avre, France Klacid I.V.
Botulinum Toxin type A 100 units/vial Powder for reconstitution for IM injection Adria S P Inc., Albuquerque, New Mexico, United States of America Occulinum Injection
Ondansetron (as the hydrochloride dihydrate) 4 mg, 8 mg Tablets Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain and Glaxo Operations UK Limited, Ware, Hertfordshire, Great Britain Zofran
Ondansetron (as the hydrochloride dihydrate) 4 mg/2 ml, 8 mg/4 ml Solution for IV and IM injection Glaxo Operations UK Limited, Barnard Castle, County Durham, Great Britain Zofran Injection
Salmeterol (as xinafoate) 25 mcg Suspension (metered dose inhaler) Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain, Laboratoires Glaxo SA, Evreux, France and Glaxo New Zealand Limited, Palmerston North Serevent Inhaler
Salmeterol (as xinafoate) 50 mcg Rotadisks Glaxo Group Research Limited, Ware, Hertfordshire, Great Britain and Laboratoires Glaxo SA, Evreux, France Serevent

Dated this 21st day of October 1993.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go9114

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Botulinum Toxin type A 100 units/vial Powder for reconstitution for IM injection Adria S P Inc., Albuquerque, New Mexico, United States of America Botox
Fleroxacin 400 mg/100 ml Solution for infusion F Hoffmann-La Roche Limited, Basle, Switzerland Quinodis
Fleroxacin 200 mg, 400 mg Tablets F Hoffmann-La Roche Limited, Basle, Switzerland Quinodis
Methadone hydrochloride 5 mg Tablet Douglas Pharmaceuticals Limited, Technical Division, Mount Roskill, Auckland Pallidone
Note: Not to be marketed as substitutable for any other methadone hydrochloride product as if the two (2) products were bioequivalent.
Isosorbide dinitrate 5 mg Tablet (sub-lingual) Apotex Inc., Weston, Ontario, Canada APO-ISDN
Paracetamol 500 mg, pseudoephedrine hydrochloride 30 mg, tripolidine hydrochloride 1.25 mg Tablet Wellcome Australia Limited, Cabarita, Sydney, New South Wales, Australia Sudafed Plus


Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1993, No 156


NZLII PDF NZ Gazette 1993, No 156





✨ LLM interpretation of page content

πŸ₯ Consent to the Distribution of Changed Medicines

πŸ₯ Health & Social Welfare
20 October 1993
Medicines Act, Distribution Consent, Changed Medicines, Pharmaceuticals
  • C. Lovelace, Director-General of Health

πŸ₯ Consent to the Distribution of New Medicines

πŸ₯ Health & Social Welfare
21 October 1993
Medicines Act, Distribution Consent, New Medicines, Pharmaceuticals
  • C. Lovelace, Director-General of Health